June 2, 2022, Beijing, China, and Singapore – Evive Biotech, a global biopharmaceutical company developing novel biologic therapies, announced today a $70 million strategic equity investment by Sino Biopharmaceutical Limited (1177.HK) (“Sino Biopharm”) and Yifan Pharmaceutical Co., Limited (002019.SZ), Evive Biotech’s largest existing shareholder.

 

This transaction follows the signing between Evive Biotech and Chia Tai Tianqing Nanjing Shunxin, a core subsidiary of Sino Biopharm, in August 2021 for an exclusive licensing agreement for the commercialization of Evive Biotech’s novel biologic drug Ryzneuta (also known as F-627) for the treatment of chemotherapy-induced-neutropenia (CIN) in China. This investment will provide funding for further clinical and commercial progress of Evive's pipeline assets, talent expansion, and R&D and manufacturing facilities. Meanwhile, Chia Tai Tianqing Nanjing Shunxin will pay 32 million RMB more for milestone payment, which up to 242 million RMB in total.

 

"We are very pleased to receive Sino Biopharm’s and Chia Tai Tianqing’s recognition and support. The successful completion of this round of financing lays a solid foundation for the long-term partnership between Evive and Sino Biopharm,” said by Dr. Simon Li, CEO and CMO of Evive Biotech. “As one of the largest pharmaceutical groups in China with leading positions in liver disease and oncology, Sino Biopharm has accumulated rich resources and deep market insights over the last several decades. We look forward to working with Sino Biopharma to provide revolutionary remedies to patients who need it most."

 

"Evive Biotech is an innovative biopharmaceutical company backed by validated science and proprietary technology platforms, a world-class management team, and international standard commercial scale manufacturing. In addition to Ryznueta™, a near commercial-stage asset, which is currently undergoing regulatory approvals in multiple territories, Evive Biotech has a strong pipeline of mid-stage and early-stage long-acting products designed for the global market," said by Stephen Tse Hsin, Executive Director of Sino Biopharm. “We see huge potential for Evive Biotech’s pipeline of inflammatory, oncology and metabolic assets and we look forward to working with Evive to quickly promote the clinical development and commercialization of high-quality and innovative products."

 

 

 

About Evive Biotech

Evive Biotech is a global biologics company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, Singapore, and China. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, Evive adopts a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house manufacture and regulatory expertise and extensive international management experience. Through partnerships with industry, physicians, and regulatory authorities, we strive to bring revolutionary remedies to the global market quickly and efficiently to address unmet medical needs, making a real and lasting difference to patients and their families worldwide.

To learn more about Evive Biotech, visit www.evivebiotech.com.

 

About Sino Biopharm

Sino Biopharmaceutical Limited and its subsidiaries are the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the full industry chain of pharmaceutical R&D platforms, intelligent production and strong sales systems. Its product offerings include a variety of biological drugs and chemical drugs, and it occupies an advantageous position in many potential therapeutic fields such as liver disease, tumors, cardiovascular and cerebrovascular diseases, orthopedics, digestive system, immune and respiratory diseases. Sino Biopharmaceutical Limited was listed on Hong Kong Stock Exchange in 2000.

To learn more about Sino Biopharm, visit www.sinobiopharm.com.

 

About Yifan Pharmaceutical

Oriented by innovation and internationalization of medical products, and under the premise of constructing a risk assurance system both at home and abroad, Yifan Pharmaceutical Co., Ltd. has focused on opening the mature market in Europe and America and other developed countries with macromolecular biologics, exploring main markets and markets of developing countries with chemical drugs of high quality, developing traditional Chinese medicines markets in China with professional and well-known brands, and the vitamin market which champions in quality, cost and scale, so as to make Yifan the expert in Medicine and Health globally.